T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to a Schedule 13G on November 16, 2026, disclosing a beneficial ownership position in MapLight Therapeutics Inc. common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 945,216 shares of MapLight Therapeutics Inc. common stock.
  • Percent of class: The 945,216 shares represent 1.7% of the class, as stated in the filing.
  • Sole voting power: The filing reports sole power to vote or direct the vote over 938,725 shares.
  • Sole dispositive power: Sole power to dispose or direct the disposition of all 945,216 shares is reported, with no shared voting or dispositive power.
  • Event date: The date of the event requiring this filing is stated as September 30, 2026.
  • Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser (Type: IA), organized in Maryland.

T. Rowe Price Investment Management Discloses Position in MapLight Therapeutics

T. Rowe Price Investment Management, Inc., headquartered at 1307 Point Street, Baltimore, MD 21231, submitted Amendment No. 2 to Schedule 13G with the SEC on November 16, 2026, covering its holdings in MapLight Therapeutics Inc. (NASDAQ:MPLT), whose principal executive offices are located at 800 Chesapeake Drive, Redwood City, CA 94063. The filing covers shares of common stock, identified by CUSIP number 56565P103, and reflects holdings as of September 30, 2026.

According to the filing, T. Rowe Price Investment Management holds an aggregate beneficial ownership of 945,216 shares, equating to 1.7% of the class. The filing reports sole voting power over 938,725 shares and sole dispositive power over the full 945,216 shares. Shared voting power and shared dispositive power are each reported as zero. Item 5 of the filing designates this as ownership of 5 percent or less of a class.

The filing was signed by Ellen York, Vice President of T. Rowe Price Investment Management, Inc., on November 16, 2026. The certification included in the filing states that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing also states that it "shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied."

What Was Disclosed

T. Rowe Price Investment Management, Inc. disclosed beneficial ownership of 945,216 shares, or 1.7%, of MapLight Therapeutics Inc. common stock as of September 30, 2026, via Amendment No. 2 to Schedule 13G, with sole dispositive power over all reported shares.